For studies of investigational new drug, NIDA requires that Lead Investigators distribute a safety report to participating Investigators within 24 hours in the following situations EXCEPT:
A. The adverse event is considered serious, unexpected, and causally related to the investigational new drug.
B. The adverse event requires a protocol revision.
C. The adverse event requires an informed consent form amendment.
D. The adverse event requires termination of the study or suspension of enrollment.
E. All of the above are correct.